Salute e Benessere
Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight
Discover more about sleep apnea treatment market segmentation @
Sleep apnea is a common disorder in which breathing repeatedly stops and starts during sleep, leading to reduced oxygen levels and disrupted rest. These interruptions, often lasting 10–20 seconds and occurring up to 100 times per hour, typically prevent deep, restorative sleep. The most prevalent form, obstructive sleep apnea (OSA), happens when throat muscles relax and block the airway. Central sleep apnea (CSA), on the other hand, is caused by the brain's failure to regulate breathing. Symptoms include loud snoring, gasping, excessive daytime sleepiness (EDS), morning headaches, poor concentration, and frequent nighttime awakenings. Complex sleep apnea, or treatment-emergent CSA, is a combination of both OSA and CSA, often identified when central apneas emerge during CPAP therapy for obstructive sleep apnea.
Sleep apnea diagnosis begins with a review of symptoms, medical history, and a physical exam. If sleep apnea is suspected, it is typically confirmed with a sleep study, either through an in-lab polysomnogram, which tracks breathing, brain activity, and heart rate, or a home sleep apnea test (HSAT) that uses fewer sensors and is suitable for those with a high likelihood of moderate to severe OSA. While screening questionnaires can help identify those at risk, only a sleep study can provide a definitive diagnosis.
The sleep apnea epidemiology section provides insights into the historical and current sleep apnea patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The sleep apnea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Management of obstructive and central sleep apnea involves addressing both the condition itself and its contributing risk factors. For individuals with mild OSA, lifestyle modifications such as weight loss, quitting smoking, and reducing alcohol intake are typically advised. Continuous Positive Airway Pressure (CPAP) remains the cornerstone of therapy, particularly for patients experiencing excessive daytime sleepiness (EDS).
However, some patients on CPAP may continue to suffer from EDS and may benefit from wake-promoting agents like modafinil, solriamfetol, and others. In cases of CSA, treatment generally involves targeting the underlying cause, such as optimizing heart failure management through appropriate medications.
A significant advancement occurred in December 2024 , with the approval of (in the US) and (in the EU) — the first and only pharmacological treatment for OSA approved in both regions. This dual GIP and GLP-1 receptor agonist is indicated for use alongside a reduced-calorie diet and increased physical activity to treat moderate-to-severe OSA in obese adults.
, a Dopamine and Norepinephrine Reuptake Inhibitor (DNRI), is approved to enhance wakefulness in adults with EDS linked to narcolepsy or OSA. It works by boosting dopamine and norepinephrine activity in the brain, making it the only EDS treatment for OSA that uses this mechanism to promote daytime alertness. SUNOSI (solriamfetol) received FDA approval in March 2019 for treating EDS in patients with narcolepsy or OSA, and subsequently, EU marketing authorization in January 2020 for the same indication.
, containing pitolisant, acts as a histamine H3 receptor antagonist/inverse agonist. It promotes wakefulness by increasing histamine levels in the brain and serves as a non-stimulant alternative to traditional agents like modafinil. Approved in Europe only, OZAWADE is indicated for EDS related to OSA in adults who continue to experience symptoms despite effective airway management. In September 2021 , the European Medicines Agency granted marketing authorization for OZAWADE for the treatment of EDS associated with OSA in adults.
To know more about sleep apnea treatment guidelines, visit @
Discover more about sleep apnea drugs in development @
The sleep apnea market dynamics are expected to change in the coming years. The sleep apnea market is driven by a confluence of factors, most notably the , especially obstructive sleep apnea, due to increasing rates of obesity, aging populations, and sedentary lifestyles. about the health risks associated with untreated sleep apnea, such as cardiovascular diseases, diabetes, stroke, and daytime fatigue, is fueling early diagnosis and treatment adoption.
, including home sleep testing devices, and the development of more targeted, user-friendly pharmacological treatments with improved safety and tolerability profiles is further propelling market growth, offering viable alternatives or adjuncts to traditional device-based therapies. Additionally,
into innovative, targeted therapies are accelerating access and market expansion across both developed and emerging economies.
Furthermore, potential therapies are being investigated for the treatment of sleep apnea, and it is safe to predict that the treatment space will significantly impact the sleep apnea market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the sleep apnea market in the 7MM.
However, several factors may impede the growth of the sleep apnea market. One of the primary challenges is , as many individuals with sleep apnea remain unaware of their condition due to vague or overlooked symptoms. among primary care providers further exacerbates this issue, delaying referrals to sleep specialists.
like polysomnography and ongoing treatment with devices such as CPAP machines can also deter patients, especially in regions with limited insurance coverage. Additionally, remains a significant hurdle, with many discontinuing use due to discomfort or inconvenience. which further impede market expansion, particularly in emerging economies.
Download the report to understand which factors are driving sleep apnea market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OSA companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key OSA companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea devices companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sleep-apnea-market-to-accelerate-substantially-at-a-cagr-of-20-during-the-study-period-20202034--delveinsight-302496530.html